Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms, Castration-Resistant 3Ovarian Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Recurrent Endometrial Endometrioid Adenocarcinoma 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Mesothelioma, Malignant 1Lymphoproliferative Disorders 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Lethal Congenital Contracture Syndrome 2 1Immunoproliferative Disorders 1Immune System Diseases 1Fibromatosis, Gingival, 2 1

Interventions

enzalutamide 1Taxes 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrent Endometrial Endometrioid Adenocarcinoma × enzalutamide × Gynecologic × Clear all
NCT02684227 2025-03-19

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
50 enrolled 14 charts
Gynecologic

Recurrent Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡